PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAbciximab
Abciximab
Reopro (abciximab) is an antibody pharmaceutical. Abciximab was first approved as Reopro on 1994-12-22. It is used to treat unstable angina in the USA. The pharmaceutical is active against integrin beta-3. In addition, it is known to target integrin alpha-IIb.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Abciximab
Tradename
Proper name
Company
Number
Date
Products
ReoproabciximabJohnson & JohnsonN-103575 DISCN1994-12-22
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
unstable anginaEFO_1000985D000789I20.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AC: Platelet aggregation inhibitors excl. heparin
— B01AC13: Abciximab
HCPCS
Code
Description
G9531
Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar
J0130
Injection abciximab, 10 mg
Clinical
Clinical Trials
47 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial infarctionD009203EFO_0000612I21—1510116
Inferior wall myocardial infarctionD056989EFO_1000983——212—5
Unstable anginaD000789EFO_1000985I20.0—121—4
St elevation myocardial infarctionD000072657————1214
Coronary artery diseaseD003324—I25.1———123
Coronary diseaseD003327—————3—3
IschemiaD007511EFO_0000556————3—3
Diabetes mellitusD003920HP_0000819E08-E13———1—1
Acute coronary syndromeD054058EFO_0005672————1—1
Middle cerebral artery infarctionD020244EFO_1001045G46.0———1—1
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.9—23——5
Balloon angioplasty coronaryD015906EFO_0003951———3——3
Pathologic constrictionD003251————1——1
Arterial occlusive diseasesD001157EFO_0009085——11——1
Acute diseaseD000208————1——1
Brain ischemiaD002545EFO_0003883I67.82——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stable anginaD060050—I20.89—1———1
Sickle cell anemiaD000755EFO_0000697D57—1———1
Carotid stenosisD016893——11———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Anterior wall myocardial infarctionD056988EFO_1000812—————11
Myocardial ischemiaD017202EFO_1001375I20-I25————11
AtherosclerosisD050197EFO_0003914I25.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAbciximab
INNabciximab
Description
Abciximab (chimeric Fab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>6V4P:C|Abciximab, heavy chain EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVY MELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH >6V4P:D|Abciximab, light chain EIVLTQSPVTLSVTPGDSVSLSCRASRDISNNLHWFQQTSHESPRLLIKYASQSMSGIPSRFSGSGSGTDFTLSINSVET EDFGMYFCQQTNSWPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB6V4P
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201584
ChEBI ID—
PubChem CID—
DrugBankDB00054
UNII IDX85G7936GV (ChemIDplus, GSRS)
Target
Agency Approved
ITGB3
ITGB3
Organism
Homo sapiens
Gene name
ITGB3
Gene synonyms
GP3A
NCBI Gene ID
Protein name
integrin beta-3
Protein synonyms
antigen CD61, CD61, GPIIIa, integrin beta 3, integrin beta chain, beta 3, integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61), Platelet membrane glycoprotein IIIa
Uniprot ID
Mouse ortholog
Itgb3 (16416)
integrin beta-3 (Q3TZC6)
Alternate
ITGA2B
ITGA2B
Organism
Homo sapiens
Gene name
ITGA2B
Gene synonyms
GP2B, ITGAB
NCBI Gene ID
Protein name
integrin alpha-IIb
Protein synonyms
alphaIIb protein, CD41, GPalpha IIb, GPIIb, integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41), platelet fibrinogen receptor, alpha subunit, platelet glycoprotein IIb of IIb/IIIa complex, Platelet membrane glycoprotein IIb, platelet-specific antigen BAK, protein phosphatase 1, regulatory subunit 93
Uniprot ID
Mouse ortholog
Itga2b (16399)
integrin alpha-IIb (Q9Z2M0)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,825 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,880 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use